Replies to post #100627 on Regen BioPharma Inc (RGBP)

[Bridget21]

In the 10 years invested, have you made $$?

[Musical Shares]

Thanks for the response.

I am going to break down your post and see if I can fill some gaps.

I'm well versed on Dr. Koos, having invested in his companies for ten years. If you don't believe me, see my posting history on Ihub. I was always an enthusiastic advocate of the science and his tickers, first with his failed company BMSN, and then RGBP and RGBPP.

I believe you. However, this doesn't solidify a faulty businessman or "scam" company.

Regen and Bio-Matrix Scientific was founded as a business model for translational medicinal platforms with an emphasis on being a super incubator of patents/technology.

In other words, and to some extent a "fringe" science company.

The problem with Koos is that he has never delivered.

This is true. However, look at the sciences and technology they were investigating and working with. Once again, "fringe" areas that were either early in its understanding or considered "not essential."

Sure a few traders have hit the jackpot, but the pattern has been one of continual disappointment with long term investors.

This is expected. Again, the science they were after tells the story.

A manager needs to step up and show his investors that a company is more than an OTC ponzi scheme. I haven't seen evidence of that. I haven't seen evidence that mRNA vaccines are the wave of the future.

Because mRNA cancer vaccines are incredibly hard to produce. The fragility of such a novelty is just but ONE problem to date.

What Regen owns is but one formulation of a Survivin peptide cancer vaccine. At this point in time, there is no clinical trial that has reached Phase 3 using a formulation on the Survivin protein.

But there is a good chance that this route and particular science/technology might be a good future for more research.

As far as why Regen can't get solid partnerships and/or funding... I am not sure why. My opinion is that the companies that are already working with this kind of science/technology don't care about their formulation.

Chances of it being successful probably are quite nil. Who wants to dump hundreds of millions on a risk like that?

I haven't seen evidence that Regen holds a unique position on research and development of immune checkpoint inhibitors.

Yes and no.

They hold a unique position on the screening process for small molecule therapeutics.

The problem isn't the research. The problem is that NR2F6 is an Orphan protein with no known ligand.

Regen's program was set up to identify an antagonist on this protein. However, there has to be a ligand to do this.

Until one is found (which in fact a step closer was achieved in possibly locating one just recently) there might not be much action.

Best of luck

[pumper_stumper]

Nice post. Rare to see such quality and realism on a pink stock board.

[HorizenBull]

Stick around a few years…BAHAHAHHAHAA

[SidVicious]

But what about those 179 articles and patents? They are undeniable! You can't stop Santa Koos from delivering us investors a really nice gift this Xmas! Can you spell BUYOUT for BILIIIIIIIOOOOONS from Lilly? They want Regen's IP bad. Thanks to OTC for giving us the low down on how this is all going to pan out. He's almost as smart as Koos!